BEOVU Versus Eylea in the Treatment of Age-related Macular Neovascular Degeneration

NCT04882956 — Not applicable, Unknown, 40 participants, Benha University

ClinicalTrials Daily · Areas · Conditions · Drugs · Sponsors ·

Outcome of Brolucizumab-dbll and Aflibercept Intravitreal Injection in the Treatment of Age-related Macular Neovascular Degeneration

Registry	NCT04882956
Status	Unknown
Phase	Not applicable
Study type	Interventional; randomized, parallel, masking: single, treatment
Enrollment	40 (Estimated)
Sponsor	Benha University (Other)
Conditions	Macula Lutea Degeneration
Interventions	intravitreal injection (Drug)
Dates	start 2020-08-05, primary completion 2021-12-01 (estimated), completion 2022-03-01 (estimated), first posted 2021-05-12, last updated 2021-05-12
Locations	1 site in United Arab Emirates

-Summary

Age-Related macular neovascularization degeneration occur is a vision threatening condition. The investigators compare the efficacy of BEOVU and Eylea intravitreal treatment in the management.

Expand all sections · Collapse all

+Detailed description

Baseline ,and postoperative 1 ,6 and 12 months full ophthalmic examination was done. Procedure included randomized intravitreal injection of Brolucizumab (BEOVU®, Genentech, South Francisco, CA) and of aflibercept (Eylea; Regeneron, Tarrytown,NY)

+Arms and interventions

Arm	Type	Interventions	Description
BEOVU	Active comparator	Drug: intravitreal injection	Intravitreal injection of BEOVU 3 loading injections ( monthly) then every 3 months
Eylea	Active comparator	Drug: intravitreal injection	Intravitreal injection of Eylea 3 loading injections ( monthly) then every 3 months

intravitreal injection (Drug), also known as BEOVU: Brolucizumab-Dbll intravitreal injection
intravitreal injection (Drug), also known as Eylea: Aflipercept intravitreal injection

+Outcome measures

Primary outcomes

Best corrected visual acuity (BCVA) [12 months]: Change in BCVA in LOG MARS(logarithm minimum angle of resolution

+Eligibility

Sex: All, ages: 18 Years to any

Inclusion Criteria:

* • Age-Related macular neovascularization degeneration

Exclusion Criteria:

* other causes of macular neovascularization degeneration
* other macular diseases

+Locations (1)

Facility	City	Country	Status
INMC	Abu Dhabi	United Arab Emirates	Recruiting

+Investigators

Tarek Elhamaky, MD, Principal investigator, Benha University

My Notes

Public

To Read Reading Read